Business context and reporting period
Important entity discrepancy: The request identifies Tevogen Inc., but the supplied Form 10-Q is for Semper Paratus Acquisition Corporation, a Cayman Islands SPAC. This summary reflects the supplied filing, not Tevogen Inc.
The unaudited report covers the quarter and six months ended June 30, 2022; it was signed August 15, 2022. Semper Paratus had not begun operating and was seeking a business combination. It had no operating revenue.
Financial performance and condition
| Metric | June 30, 2022 / period |
|---|---|
| Quarter net income | $206,998 |
| Six-month net income | $181,010 |
| Quarter general and administrative expense | $258,585 |
| Six-month general and administrative expense | $541,464 |
| Other income, six months | $722,474, including $468,724 unrealized trust investment gains and $253,750 warrant fair-value gain |
| Operating cash used, six months | $158,936 |
| Cash outside trust | $185,645 |
| Trust account assets | $352,384,530 |
| Working capital | $335,521 |
| Total liabilities | $15,125,984, including $14,700,000 deferred underwriting fees contingent on completing a business combination |
| Long-term debt | None reported; no working-capital loan borrowings at quarter-end |
Reported earnings per share rounded to $0.00 for both share classes. Operating margins are not meaningful because the company had no operating revenue. The filing does not provide a clear quarter-versus-prior-year comparable operating result; the presented 2021 comparison is the period from inception through June 30, 2021.
Changes versus prior periods
Compared with December 31, 2021, cash outside trust declined from $344,581 to $185,645; current assets declined from $791,191 to $594,755; and current liabilities increased from $59,375 to $259,234. Trust assets increased from $351,915,805 to $352,384,530. The private-placement warrant liability fell from $420,500 to $166,750, generating a fair-value gain. Accumulated deficit narrowed from $14,229,052 to $14,048,042.
The six-month net income was driven by non-operating gains, not business operations. The filing’s MD&A appears to reverse or misstate the quarter and six-month net income figures; the financial statements report $206,998 for the quarter and $181,010 for six months.
Outlook, risks and unusual items
- The SPAC had until February 8, 2023 to complete a business combination. If unsuccessful, it was required to cease operations, redeem public shares from the trust account and liquidate. Management said this mandatory liquidation raised substantial doubt about the company’s ability to continue as a going concern.
- The notes state the company would need additional capital for working-capital needs and that sponsor or insider loans were possible but not committed. Management cautioned financing might not be available. This contrasts with the MD&A statement that it did not believe additional funds would be needed.
- The trust account was principally invested in U.S. Treasury securities. The company reported no material market or interest-rate risk due to short maturities.
- COVID-19 and the Russia/Belarus military action and related sanctions could adversely affect the company or its search, but specific effects were not determinable.
- There was no litigation, no reported off-balance-sheet arrangement, and no material change to previously disclosed risk factors. Management assessed disclosure controls as effective and reported no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Semper Paratus Acquisition Corporation, not Tevogen Inc.
- Reconcile the MD&A’s inconsistent net-income period figures against the financial statements.
- Monitor the business-combination deadline, financing runway outside the trust, and the going-concern warning.
- Assess redemption levels, deferred underwriting fees, and the potential dilution and value of founder shares and warrants in any proposed transaction.